Warning: Declaration of Suffusion_MM_Walker::start_el($output, $item, $depth, $args) should be compatible with Walker_Nav_Menu::start_el(&$output, $item, $depth = 0, $args = NULL, $id = 0) in /home/hygiol5/public_html/wp-content/themes/suffusion/library/suffusion-walkers.php on line 39
Feb 152013

The Hygiology Post is presenting information about a company that seems to have much potential to help many people. Both 2012 and 2013 appear to be pivotal years in determining how helpful the patented technologies may actually be for people.

Senesco Technologies has continued to update information on its web site (https://www.senesco.com; obtained on 2-15-13). As a matter of disclosure : The author continues to be a current shareholder in the company.

The Senesco Technologies web site ( https://www.senesco.com/newsitem.php?id=272; obtained on 2-15-13) has today posted relevant information about its about its research. Here is an excerpt :


Senesco Technologies Reports Second Quarter Fiscal 2013 Financial Results

Senesco Technologies Reports Second Quarter Fiscal 2013 Financial Results

BRIDGEWATER, N.J. (February 15th, 2013) – Senesco Technologies, Inc. (“Senesco” or the “Company”) (OTCQB: SNTI) today reported financial results for the second quarter of fiscal year 2013 which ended on December 31, 2012.

Highlights of the second quarter and recent weeks include:

• The Company completed an offering of common stock and warrants for gross proceeds of $3,000,000.

• The Company expanded its Phase 1b/2a clinical trial to include Diffuse Large B-Cell Lymphoma and Mantle Cell Lymphoma.

• The first Diffuse Large B-Cell Lymphoma patient was treated in the Phase 1b/2a study.

• A poster describing the ongoing SNS01-T study in multiple myeloma was presented at the 2012 Annual Meeting of the American Society of Clinical Oncology.

• The Company presented at RetailInvestorConferences.com.

‘We are pleased with the current results of the SNS01-T Phase 1b/2a trial even at the low starting dose’ said Leslie J. Browne, Ph.D., President and CEO of Senesco. ‘We look forward to reporting on the results of the remaining cohorts of the trial using SNS01-T at higher dose levels this year.’ ”


The Hygiology Post ® welcomes feedback from readers as to whether the articles (individually and/or collectively) help fulfill its vision and mission.


Louis DeCola, Jr.                                    © 2012 The Hygiology Post ®